Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company reported a revenue of 15.028 billion RMB (+22.6% YoY) and a net profit of 5.555 billion RMB (+27.1% YoY) for the year 2025, with innovative drugs contributing 12.354 billion RMB (+30.4% YoY), accounting for 82.2% of total revenue [1][7] - The growth is driven by both innovation and business development (BD), indicating a strong outlook for continued growth [1] Revenue Breakdown - Oncology segment revenue reached 9.974 billion RMB (+23% YoY), primarily due to the strong performance of core products like Amivantamab and milestone income from GSK [2] - Anti-infection revenue was 1.586 billion RMB (+8% YoY), driven by the sales of Adefovir [2] - CNS segment revenue was 1.310 billion RMB (-5% YoY), with the negative impact from centralized procurement on generic drugs largely mitigated [2] - Revenue from metabolic and other diseases surged to 2.158 billion RMB (+67% YoY), mainly due to milestone payments from Merck [2] R&D Progress - The company has 8+1 innovative drugs and 15+3 indications approved, with 40+ molecules in over 70 clinical trials [3] - Key pipelines include Amivantamab, HS-20093, HS-20089, HS-20094, and HS-20117, with several in Phase III clinical trials [3] International Collaboration - The company has achieved at least one high-quality external authorization each year for the past three years, accumulating 542 million USD in upfront payments and a total of 8.8 billion USD in potential revenue from five projects in Europe and the US [4] - Ongoing collaborations with GSK, Regeneron, and MSD are progressing positively, with several projects in various clinical stages [4] Profit Forecast and Valuation - The company’s net profit forecasts for 2026 and 2027 have been raised to 6.228 billion RMB and 6.602 billion RMB, respectively, reflecting an increase of 14% and 15% [5] - The target price is set at 43.68 HKD, based on a sum-of-the-parts (SOTP) valuation of 264.5 billion HKD [5]

Group 1: Company Project Progress - The company has over 30 research and development projects, with global patent expirations concentrated between 2028 and 2033. Some products, such as Vabigatran and Rosuvastatin, are already in the registration submission stage [2] - The company plans to continuously add new product projects each year to create a tiered product structure. Additionally, its affiliate, Boya Biotech, focuses on high-difficulty specialty formulations, which may lead to business synergies [2] Group 2: Business Development - On February 4, 2026, the company announced that the raw material for Edoxaban passed the approval of the National Medical Products Administration (NMPA), which is expected to boost sales in the domestic market and synchronize with international market expansion [3] - The company is implementing a "first generic, one supply" strategy, with approved new products like Vildagliptin and Agomelatine set to join the domestic sales lineup and actively expand into emerging markets [3] Group 3: Business Status - Currently, domestic business revenue accounts for approximately 20% of total revenue. The company plans to bind with leading generic drug companies as main suppliers, with an average of 3-5 core customers per product, to further expand its domestic market share [4] - Seventeen technically mature new products are capable of global supply, and the company will rely on the early layout of the supply chain for products with upcoming patent expirations [4] Group 4: Company Situation - The company has recently obtained several invention patents, such as methods for catalyst regeneration, but has not disclosed specific timelines for industrialization [5] - As of the end of January 2026, there was a net outflow of main funds, but market sentiment changes should be observed in conjunction with subsequent performance and order fulfillment [5]

Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Jiangsu Weiqida Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Agomelatine, indicating compliance with national drug approval standards and allowing for domestic production and sales [1][3]. Group 1: Drug Information - The chemical raw material drug is Agomelatine, with registration number Y20240000572 and packaging specifications of 20kg per barrel [1]. - Agomelatine acts on melatonin receptors MT1 and MT2 and antagonizes 5-HT2C to restore disrupted biological rhythms, primarily used for treating major depressive disorder in adults [2]. - As of 2023, the global consumption of Agomelatine raw material is reported to be 5,735.23 kg [2]. Group 2: Company Impact - The approval of Agomelatine for domestic production will enhance the company's specialty raw material drug portfolio and positively influence future development [3]. - The impact on the company's current operating performance is not expected to be significant [3].

Core Viewpoint - The announcement by Guoyao Modern regarding the approval of the raw material drug Agomelatine by the National Medical Products Administration indicates a significant advancement in the company's product portfolio, particularly in the treatment of adult depression [1] Group 1: Company Developments - Guoyao Modern's wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., has received the approval notice for the listing application of the raw material drug Agomelatine [1] - The registration standard number for the chemical raw material drug is YBY73032025 [1] Group 2: Product Information - Agomelatine acts primarily through the agonism of melatonin receptors MT1 and MT2, along with the antagonism of 5-HT2C, to restore disrupted biological rhythms in patients, thereby exerting an antidepressant effect [1] - The clinical application of Agomelatine is mainly focused on the treatment of adult depression [1]

Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of the raw material drug Agomelatine [1] Group 1: Company Developments - Guoyao Modern's subsidiary has been granted a marketing approval for Agomelatine, a drug primarily used for treating adult depression [1] - Agomelatine works by activating melatonin receptors MT1 and MT2 and antagonizing 5-HT2C, which helps restore disrupted biological rhythms and exerts antidepressant effects [1] Group 2: Industry Context - The approval of Agomelatine aligns with the growing demand for effective treatments for depression, highlighting the importance of innovative therapies in the pharmaceutical industry [1]

Investment Rating - The report does not explicitly state an investment rating for the antidepressant drug industry Core Insights - Depression disorders are the most common mental disorders, characterized by persistent low mood, loss of pleasure, and decreased energy. The etiology remains unclear, with various hypotheses including the monoamine hypothesis and glutamatergic system abnormalities [5][23] - There are unmet clinical needs in depression treatment, including limited efficacy of current first-line antidepressants, slow onset of action, and the need for precision treatment for different subtypes and special populations [5][27] - The current market for antidepressants in China is substantial, with over 8 billion yuan in hospital sales, where SSRIs and SNRIs account for approximately 60% of the market share [5][6] - New drug development is focusing on deepening monoamine research, exploring amino acid classes, and other mechanisms, with a gradual entry into a harvest period for innovative drugs [5][6] Summary by Sections Unmet Clinical Needs - Current first-line antidepressants like SSRIs have limited efficacy, with about one-third of patients not achieving remission after multiple treatment steps [27] - The onset of current antidepressants is slow, typically requiring 1-4 weeks for initial improvement and 4-8 weeks to reach treatment goals, posing risks for patients during acute phases [27][28] - There is a need for precision treatment for different subtypes of depression and special populations such as children and the elderly [27] Market Overview - The antidepressant market in China saw over 8 billion yuan in sales, with SSRIs leading at 3.58 billion yuan (43.44% market share) and SNRIs at 1.42 billion yuan (17.18% market share) [5][6] - The top-selling antidepressants include escitalopram oxalate, agomelatine, and sertraline [5] Drug Development Trends - The report highlights ongoing research into monoamine neurotransmitter drugs, with 128 clinical-stage products targeting various mechanisms [5][6] - Innovative drugs are gradually entering the market, with one local innovative drug already launched and over twenty in clinical trials [5][6]

Core Viewpoint - The National Drug Centralized Procurement Office has announced the new centralized procurement document, emphasizing principles of clinical stability, quality assurance, prevention of collusion, and reduction of competition pressure in the pharmaceutical industry [1][3]. Summary by Sections Centralized Procurement Announcement - The announcement requires participating drugs to obtain valid domestic registration by September 28 and complete information submission on the National Medical Insurance Service Platform, with the bidding ceremony scheduled for October 21, 2025 [1]. Changes in Procurement Rules - The new procurement rules introduce a "benchmark price" for the same drug category, set at 50% of the average unit comparable price of validly declared companies and the higher value of the lowest unit comparable price. Companies can qualify for selection if their bid is below 1.8 times the benchmark price, a shift from the previous model that focused solely on the lowest price [3]. Participation and Reporting - A total of 46,359 medical institutions participated in the reporting, with 77% reporting by brand name and 23% by generic name. The drug list remains unchanged with 55 varieties, but mainstream specifications and prices have been noted [3]. Sodium Bicarbonate Injection Reporting - The total reported quantity of sodium bicarbonate injection across 31 provinces reached 71.5665 million units, with unspecified brands accounting for 47.45% of the total [5][9]. Manufacturer Performance - Among the specified brands, six manufacturers reported over 1 million units, with Shijiazhuang Fourth Pharmaceutical Company leading at 9.6542 million units, followed by Hebei Tiancai Pharmaceutical Co., Ltd. at 5.6166 million units [7][9]. Regional Preferences - Regional preferences for manufacturers are evident, with Yunnan showing a strong preference for Hebei Tiancai Pharmaceutical, while Shijiazhuang Fourth Pharmaceutical has a balanced national coverage [9][10]. Market Dynamics Ahead of Bidding - As the bidding date approaches, the market dynamics for sodium bicarbonate injection are expected to shift, influenced by brand preferences and the flow of unspecified brands, with companies that possess capacity, quality, and clinical recognition likely to emerge as winners in this round of procurement [10].

Core Insights - The prevalence of insomnia among adults in China is increasing, with the number of affected individuals expected to reach 300 million by 2024 and 330 million by 2030 [1] - The market for insomnia medications in China is projected to grow from 12.28 billion yuan in 2021 to 15.12 billion yuan by 2025, and further to 21.19 billion yuan by 2030 [1] - New dual orexin receptor antagonists (DORAs) have recently been approved for the Chinese market, targeting a broader population of insomnia sufferers [1][3] Market Trends - The sales of traditional hypnotics have shown rapid growth, with sample hospitals reporting sales of 1.641 billion yuan in 2021, and public hospitals spending 5.481 billion yuan on these medications [2] - Despite the growth, over 40% of the population suffers from sleep issues, with less than 30% seeking treatment, indicating a significant unmet demand [2] Drug Development - Traditional insomnia medications, primarily benzodiazepines, have side effects such as daytime drowsiness and cognitive impairment, which DORAs aim to overcome [2][3] - DORAs work by blocking the binding of orexin neuropeptides to their receptors, thus inducing natural sleep without the extensive sedation associated with traditional drugs [2][3] Regulatory and Market Entry - Two new DORA medications, approved in May and June 2023, are now available in hospitals and on e-commerce platforms, with intentions to negotiate for inclusion in the national medical insurance directory [3][4] - The current focus of domestic innovative pharmaceutical companies has been on oncology and autoimmune diseases, leading to fewer developments in insomnia treatments [4] Competitive Landscape - The insomnia medication market is competitive, with various options available, including traditional and herbal remedies [5] - Agomelatine, a melatonin receptor agonist, has shown significant sales growth, reaching 640 million yuan in 2022, a 29.6% increase year-on-year [5] Treatment Recommendations - Non-pharmacological interventions such as relaxation techniques and aerobic exercise are recommended for occasional insomnia, while persistent issues should be evaluated by specialists [6]

Core Insights - The prevalence of insomnia among adults in China is increasing, with the number of affected individuals expected to reach 300 million by 2024 and 330 million by 2030 [1] - The sleep economy market in China is expanding, with the insomnia medication market projected to grow from 12.28 billion yuan in 2021 to 15.12 billion yuan by 2025, and 21.19 billion yuan by 2030 [1] - New dual orexin receptor antagonists (DORAs) have been approved for the Chinese market, targeting the general population suffering from insomnia [1][2] Market Dynamics - The traditional insomnia medication market, primarily consisting of benzodiazepines, has seen rapid growth, with sales in sample hospitals reaching 1.641 billion yuan in 2021 [1] - Despite the growth, a significant portion of the insomnia population remains untreated, with over 40% of the population experiencing sleep issues and less than 30% seeking medical help [2] - DORAs present a new opportunity as they do not fall under the strict regulations of controlled substances, making them more accessible to the general public [2] Product Development - Two new DORA medications, Lemborexant and Daridorexant, were approved in China in May and June 2023, respectively, and are now available on e-commerce platforms and retail pharmacies [3] - Both medications have applied for inclusion in the national medical insurance directory, indicating potential for price negotiations and broader access [3] - Current clinical trials for DORA medications include YZJ-1139 and HEC-83518, indicating ongoing innovation in the insomnia treatment space [3] Competitive Landscape - The insomnia medication market is competitive, with various options available, including traditional medications and newer alternatives like melatonin receptor agonists [4] - Agomelatine, a melatonin receptor agonist, has shown significant sales growth, reaching 640 million yuan in 2022, with a year-on-year increase of 29.6% [4] - The dual orexin receptor antagonists are positioned to address unmet needs in the insomnia treatment market, particularly for patients who have not previously used related medications [3][4] Treatment Approaches - Non-pharmacological interventions such as relaxation training, deep breathing, meditation, and aerobic exercise are recommended for occasional insomnia, reducing the need for medication [5] - For persistent insomnia, a thorough evaluation by a specialist is advised to rule out other underlying issues before considering medication [5]

Group 1: Financial Performance Overview - The company achieved a sales revenue of 427.42 million CNY, a year-on-year increase of 11.88% [2] - Foreign sales amounted to 348.34 million CNY, growing by 6.66%, while domestic sales reached 79.09 million CNY, up by 42.59% [2] - New products generated sales of 195.19 million CNY, reflecting a growth of 7.16%, whereas mature products contributed 232.24 million CNY, increasing by 16.17% [2] - CMO/CDMO business saw a revenue decline of 19.05%, totaling 32.30 million CNY [2] - Net profit was reported at 58.49 million CNY, a decrease of 15.91%, with a net profit margin of 13.68%, down by 4.52 percentage points [2] Group 2: Cost and Profitability Analysis - Gross margin stood at 31.45%, down by 3.08 percentage points [2] - Sales expenses decreased by 8.92%, while management expenses increased by 1.04% [2] - R&D expenses rose by 20.14% due to an increase in R&D personnel [2] - The decline in gross margin was attributed to low prices of mature products and increased depreciation costs [3] Group 3: Market and Product Insights - Non-contract custom business revenue increased by 15.48%, while contract custom project revenue fell by 19.05% [2] - Sales of pharmaceutical raw materials rose by 20.06%, despite a gross margin decline of 3.70 percentage points [3] - Domestic sales saw a significant increase of 42.59%, with a gross margin improvement of 9.30 percentage points [3] - The company plans to enhance its domestic raw material market presence and increase the number of API registrations [4] Group 4: Future Growth Strategies - The company aims to continue launching new products, with a focus on becoming a leading supplier of generic drugs [4] - CMO/CDMO business is expected to grow significantly by 2027-2028, with new projects being actively pursued [6] - The second-phase construction of the second plant is ongoing, expected to contribute to production capacity by 2026 [6] - The company anticipates a total production capacity of 2 billion CNY in the next 3-5 years [10] Group 5: Investor Q&A Highlights - New products are projected to generate 195 million CNY in the first half of 2025, with 160 million CNY from high-end regulated markets [7] - The company is focusing on high-difficulty specialty formulations and will not pursue general solid oral formulations [10] - Future R&D investments will prioritize raw materials, CMO/CDMO, and specialty formulations [11]